Article thumbnail

Neurobiology of Depression and Anxiety in Parkinson's Disease

By Osamu Kano, Ken Ikeda, Derek Cridebring, Takanori Takazawa, Yasuhiro Yoshii and Yasuo Iwasaki


Depression and anxiety are common in Parkinson's disease (PD) and have important consequences on quality of life. These have long been recognized as frequent accompanying syndromes of PD, and several reports suggest that these are the causative process or risk factors that are present many years before the appearance of motor symptoms. The neurochemical changes in PD involving dopamine, norepinephrine, and serotonin might be related to the pathophysiology of depression and anxiety, but this is still not clear. Several studies showed that anxiety in PD patients occurs earlier than depression, during premotor phase, suggesting that there may be a link between the mechanisms that cause anxiety and PD. Whereas a recent study reported that PD patients with depression and anxiety were associated with different demographic and clinical features

Topics: Review Article
Publisher: SAGE-Hindawi Access to Research
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2000). A .M .K u o p i o ,R .J .M a r t t i l a ,H .H e l e n i u s ,M .T o i v o n e n
  2. (2009). A controlled trial of antidepressants in patients with Parkinson disease and depression,”
  3. (2008). a n o ,K .I k e d a ,T .K i y o z u k ae ta l . ,“ B e n e fi c i a le ffect of pramipexole formotorfunctionanddepressioninParkinson’s disease,”
  4. (2009). a r s l a n d ,L .M a r s h ,a n dA .S c h r a g ,“ N e u r o p s y c h i a t r i c symptoms
  5. (2000). Anxiety disorders and depressive disorders preceding Parkinson’s disease:a case-controlstudy,”
  6. (2010). Anxiety disorders in Parkinson’s disease: prevalence and risk factors,”
  7. (2010). Anxious and depressive symptoms in Parkinson’s disease:
  8. (2000). Association of coffee and caffeine intake with the risk of Parkinson disease,”
  9. (2010). Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease,”
  10. (2002). Beyond the iron mask:towards better recognition and treatment of depression associated with Parkinson’s disease,”
  11. (1998). Brain mechanisms of social anxiety disorder,”
  12. (2000). brain norepinephrine and dopamine release in treatmentrefractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders,”
  13. (2006). C h a u d h u r i ,D .G .H e a l y ,a n dA .H .S c h a p i r a ,“ N o n -motor symptoms of Parkinson’s disease: diagnosis and management,”
  14. (1985). Cerebrospinal fluid monoamine and monoamine metabolite concentrations in melancholia,”
  15. (2005). e m y ,M .D o d e r ,A .L e e s ,N .T u r j a n s k i ,a n dD .B r o o k s , “Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system,” Brain,v o l .
  16. (2008). Early Parkinson’s disease and non-motor issues,”
  17. (2002). Ensinck et al., “Increased risk of Parkinson’s disease after depression: a retrospective cohort study,”
  18. (2005). F.J.VajdaandC.Solinas,“Currentapproachestomanagement of depression in Parkinson’s disease,”
  19. (2009). Hern´ an, “Use of antidepressants and the risk of Parkinson’s disease: a prospective study,”
  20. (2001). M a t h e w ,J .D .C o p l a n ,a n dJ .M .G o r m a n ,“ N e u r o b i o l o g -ical mechanisms of social anxiety disorder,”
  21. (2010). Maraganoreet al.,“Anxious personality predicts an increased risk of Parkinson’s disease,”
  22. (1999). Masterman,“Depression in patients with Parkinson’s disease,”
  23. (1981). Mental disorders from low-dose bromocriptine,” New England
  24. (2008). Nonmotor symptoms as presenting complaints in Parkinson’s disease: a clinicopathological study,”
  25. (2010). Occurrence of depression and anxiety prior to
  26. (2010). Parkinson disease: depression and anxiety in Parkinson disease,”
  27. (2003). Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: anationalmulticentre prospective randomizedstudy,”
  28. Pramipexole for the treatment ofdepressivesymptomsinpatientswithParkinson’s disease:arandomised,double-blind,placebo-controlled trial,”
  29. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study,”
  30. (2009). Prevalence of anxiety disorders and anxiety subtypes
  31. (2006). Quality of life and depression in Parkinson’s disease,”
  32. (1999). Review of community prevalence of depression in later life,”
  33. (2007). Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease,”
  34. (2008). Svatova et al., “Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study,”
  35. (2003). W e i s s k o p f ,H .C h e n ,M .A .S c h w a r z s c h i l d ,I .K a w a c h i , andA. Ascherio, “Prospective study ofphobicanxiety andrisk of Parkinson’s disease,” Movement Disorders,v o l .1 8 ,n o .6 ,p p .
  36. (2002). Weiner,“Non-recognition ofdepressionandothernon-motor symptoms
  37. (2010). When does Parkinson disease start?”